Generium Will Test a Nasal Vaccine for COVID-19 on Volunteers

Research to begin as early as December 2021

Generium, located in Volginsky village, Petushinsky district, Vladimir region, begins clinical trials of a new vaccine against coronavirus. Its peculiarity is that it will be produced in the form of a spray.

Permission for clinical trials of the nasal vaccine GNR-099 was issued by the Ministry of Health of the Russian Federation. It is planned to study its safety and compare its immunogenicity (ability to cause an immune response) with the Gam-Covid Vaccine (Sputnik V).

According to TASS with reference to the State Register of Medicines, the study of the vaccine in the form of a nasal spray will be conducted by Generium in cooperation with the Gamaleya Research Center. Trials will begin in December 2021 in 13 medical institutions in Moscow, St. Petersburg, Nizhny Novgorod, Saratov, Saransk, Yaroslavl, Voronezh and Smolensk.

The study will involve 1320 healthy volunteers. It is noted that the nasal vaccine will be two-component, with each dose including 0.5 ml of the drug.

Original publication

Related News

Back to top button